Trials Sponsors Conditions Drugs Pricing

Conditions

Diffuse Large B Cell Lymphoma

Keywords

DLBCLReal time molecular characterization

Outcome Measures

Primary Outcomes (1)

Real time report of molecular characterization
To timely report the molecular characterization (pathogenic, diagnostic, prognostic, theranostic markers) of previously untreated DLBCL patients prior to day 38(i.e. 38 days after starting inductive chemotherapy regimen, in at least 80% of enrolled patients
38 days (i.e. 38 days after starting inductive chemotherapy regimen

Interventions

Biological samples collectionProcedure

In addition to collection and characterization of tumor biopsy samples done for diagnosis (standard care), collection of blood samples at study entry for further biological analyses.

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Patient ≥ 18 years old with prior untreated DLBCL

You may qualify if:

DLBCL patients that will be eligible in front-line treatment for a combination of anthracycline-based chemotherapy plus anti-CD20 monoclonal antibody,Rituximab: R-CHOP 14, R-CHOP 21, R mini-CHOP, R-ACVBP, R-COPADEM. Patients treated with R-CHOP associated with an experimental drug ((polatuzumab, tazemetostat, venetoclax, entospletinib, lenalidomide, ibrutinib, anti PD1/anti PDL1 ….)

Sponsors & Collaborators

The Lymphoma Academic Research Organisation
Otherlead

Study Sites (15)

CHU Caen

Caen, 14000, France

Hopital Henri Mondor

Créteil, 94010, France

CHU Le Bocage

Dijon, 21034, France

CH Départemental

La Roche-sur-Yon, 85925, France

CHU Claude Hurriez

Lille, 59037, France

CHU Montpellier

Montpellier, 34295, France

CHU de Nantes

Nantes, 44093, France

Biospecimen

Retention: SAMPLES WITH DNA

Blood samples are collected at time of enrollment in the trial.

MeSH Terms

Conditions

Lymphoma, Large B-Cell, Diffuse

Condition Hierarchy (Ancestors)

Lymphoma, B-CellLymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Officials

Fabrice Jardin, Pr
Lymphoma Study Association
PRINCIPAL INVESTIGATOR
Christiane Copie, Pr
Lymphoma Study Association
PRINCIPAL INVESTIGATOR

Enrollment

219 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

April 3, 2017

First Posted

April 7, 2017

Study Start

May 9, 2017

Actual (reported)

Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (15)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (15)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations